Skip to main content
Livermore
Livermore
ZHEN

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q1 2022

Holdings as of Mar 31, 2022, filed May 13, 2022. Long positions only; changes compare share counts with Q4 2021.

Institution overview
Positions
48
+2 vs. Q4 2021
Portfolio value
$252.2M
+$17.8M (+7.6%) vs. Q4 2021
Filed
May 13, 2022
SEC
Holdings of Affinity Asset Advisors, LLC in Q1 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
NARIInari Medical, Inc.Stock220,000$19.9M7.9%+95,000+76.0%AddedHistory
MORFMorphic Holding, Inc.COM465,654$18.7M7.4%+66,352+16.6%AddedHistory
KURAKura Oncology, Inc.COM924,147$14.9M5.9%+364,147+65.0%AddedHistory
ASNDAscendis Pharma A/SSPONSORED ADR120,000$14.1M5.6%+120,000NewHistory
SWTXSpringWorks Therapeutics, Inc.COM247,000$13.9M5.5%−51,545−17.3%ReducedHistory
KDNYChinook Therapeutics, Inc.COM845,155$13.8M5.5%+290,000+52.2%AddedHistory
ESTAEstablishment Labs Holdings Inc.COM174,500$11.8M4.7%+97,000+125.2%AddedHistory
Retrophin Inc761299AB2NOTE 2.500% 9/1–$11.5M4.6%–––
AZNAstraZeneca PLCSPONSORED ADR160,000$10.6M4.2%+160,000NewHistory
ZNTLZentalis Pharmaceuticals, Inc.COM207,500$9.57M3.8%+90,000+76.6%AddedHistory
Nanostring Technologies Inc63009RAD1NOTE 2.625% 5/0–$7.75M3.1%–New–
MDGLMadrigal Pharmaceuticals, Inc.COM75,000$7.36M2.9%+10,000+15.4%AddedHistory
PTGXProtagonist Therapeutics, IncCOM300,000$7.10M2.8%+58,881+24.4%AddedHistory
ARYEARYA Sciences Acquisition Corp VCLASS A ORD SHS702,500$6.83M2.7%00.0%UnchangedHistory
RPTXRepare Therapeutics Inc.COM468,905$6.68M2.6%+197,127+72.5%AddedHistory
LNTHLantheus Holdings, Inc.Stock115,000$6.36M2.5%+115,000NewHistory
NSTGNS Wind Down Co., Inc.COM171,592$5.96M2.4%+171,592NewHistory
VINCVincerx Pharma, Inc.COM NEW1,374,098$5.50M2.2%+238,733+21.0%AddedHistory
RCKTRocket Pharmaceuticals, Inc.COM300,000$4.76M1.9%+135,000+81.8%AddedHistory
BridgeBio Pharma, Inc.10806XAD4NOTE 2.250% 2/0–$4.68M1.9%–New–
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$4.38M1.7%–––
CLDXCelldex Therapeutics, Inc.COM NEW125,000$4.26M1.7%+25,000+25.0%AddedHistory
Bellus Health Inc New07987C204COM NEW600,000$4.13M1.6%+100,000+20.0%Added–
CBAYCymaBay Therapeutics, Inc.COM1,272,244$3.96M1.6%+150,000+13.4%AddedHistory
HZNPHorizon Therapeutics Public Ltd CoSHS30,000$3.16M1.3%+30,000NewHistory
OBIOOrchestra BioMed Holdings, Inc.ORD SHS300,000$2.97M1.2%00.0%UnchangedHistory
Medicus Sciences AcquisitionG5960S108CL A SHS300,000$2.93M1.2%00.0%Unchanged–
TVTXTravere Therapeutics, Inc.COM100,000$2.58M1.0%+50,000+100.0%AddedHistory
CERECerevel Therapeutics Holdings, Inc.COM70,000$2.45M1.0%−155,000−68.9%ReducedHistory
XENEXenon Pharmaceuticals Inc.COM80,000$2.45M1.0%−70,500−46.8%ReducedHistory
NAUTNautilus Biotechnology, Inc.COM559,019$2.43M1.0%−490,702−46.7%ReducedHistory
GBTGlobal Blood Therapeutics, Inc.COM70,000$2.42M1.0%+70,000NewHistory
ACRSAclaris Therapeutics, Inc.COM100,000$1.72M0.7%−300,000−75.0%ReducedHistory
CNTXContext Therapeutics Inc.COM777,610$1.69M0.7%+777,610NewHistory
Bio Green Med Solution, Inc.23254L603COM400,000$1.22M0.5%00.0%Unchanged–
LIANYLianBioSPONSORED ADS325,000$1.21M0.5%+252,594+348.9%AddedHistory
SNCEScience 37 Holdings, Inc.COM221,382$1.18M0.5%+71,382+47.6%AddedHistory
KRTXKaruna Therapeutics, Inc.COM7,500$951.0K0.4%+7,500NewHistory
VRDNViridian Therapeutics, Inc.COM50,000$925.0K0.4%+50,000NewHistory
RCORRenovacor, Inc.COM199,490$846.0K0.3%+74,490+59.6%AddedHistory
CRISCuris IncCOM NEW350,000$833.0K0.3%−300,000−46.2%ReducedHistory
CNTACentessa Pharmaceuticals plcSPONSORED ADS65,282$586.0K0.2%−353,862−84.4%ReducedHistory
CALACalithera Biosciences, Inc.COM1,000,000$404.0K0.2%+1,000,000NewHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$328.0K0.1%−2,796−1.5%Reduced–
HYPRHyperfine, Inc.COM CL A76,162$270.0K0.1%00.0%UnchangedHistory
BPMCBlueprint Medicines CorpCOM1,988$127.0K0.1%+1,988NewHistory
Renovacor, Inc.75989E114*W EXP 99/99/99975,000$26.0K<0.1%00.0%Unchanged–
Medicus Sciences AcquisitionG5960S124*W EXP 02/12/20233,333$14.0K<0.1%00.0%Unchanged–

Options (11)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q1 2022
SecurityClassPutsCalls
SPYSPDR S&P 500 ETF TrustETF$338.7M–
SWTXSpringWorks Therapeutics, Inc.COM$9.03M–
PMVPPMV Pharmaceuticals, Inc.COM–$6.61M
PTGXProtagonist Therapeutics, IncCOM$5.11M–
CRSPCRISPR Therapeutics AGNAMEN AKT–$3.45M
RLAYRelay Therapeutics, Inc.COM–$2.25M
LNTHLantheus Holdings, Inc.Stock$2.21M–
AUPHAurinia Pharmaceuticals Inc.COM–$2.17M
BEAMBeam Therapeutics Inc.COM–$1.72M
ATHXAthersys, IncCOM$858.0K–
CELUCelularity IncCOM CL A$697.0K–

Sold out since Q4 2021 (11)

Positions held at the end of Q4 2021 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q4 2021
SecurityClassShares in Q4 2021Value in Q4 2021% of portfolio in Q4 2021History
ARNAArena Pharmaceuticals IncCOM NEW100,000$9.29M4.0%History
BBIOBridgeBio Pharma, Inc.COM494,046$8.24M3.5%History
CYTKCytokinetics IncCOM NEW145,552$6.63M2.8%History
ARYDARYA Sciences Acquisition Corp IVCL A400,000$3.97M1.7%History
SNDXSyndax Pharmaceuticals IncCOM175,000$3.83M1.6%History
Environmental Impact Acqu Co29408N106COM CL A300,000$2.98M1.3%–
MRTXMirati Therapeutics, Inc.COM20,000$2.93M1.3%History
PRCTPROCEPT BioRobotics CorpCOM100,000$2.50M1.1%History
NTLAIntellia Therapeutics, Inc.COM10,000$1.18M0.5%History
ALDXAldeyra Therapeutics, Inc.COM100,759$403.0K0.2%History
IOVAIovance Biotherapeutics, Inc.COM20,000$382.0K0.2%History